3 Drugs Stocks Driving The Industry Higher

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

One out of the three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 13 points (0.1%) at 17,609 as of Tuesday, June 30, 2015, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,652 issues advancing vs. 1,385 declining with 154 unchanged.

The Drugs industry currently sits up 1.7% versus the S&P 500, which is unchanged. Top gainers within the industry include bluebird bio ( BLUE), up 4.9%, Opko Health ( OPK), up 4.1%, Alnylam Pharmaceuticals ( ALNY), up 3.8%, Incyte ( INCY), up 2.2% and Illumina ( ILMN), up 1.7%. On the negative front, top decliners within the industry include AstraZeneca ( AZN), down 1.5%, Sanofi ( SNY), down 1.3%, GlaxoSmithKline ( GSK), down 1.1%, Novo Nordisk A/S ( NVO), down 0.6% and Novartis ( NVS), down 0.5%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Amgen ( AMGN) is one of the companies pushing the Drugs industry higher today. As of noon trading, Amgen is up $0.78 (0.5%) to $152.38 on average volume. Thus far, 1.8 million shares of Amgen exchanged hands as compared to its average daily volume of 3.2 million shares. The stock has ranged in price between $151.51-$153.91 after having opened the day at $153.24 as compared to the previous trading day's close of $151.60.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses for the treatment of illness in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine. Amgen has a market cap of $120.1 billion and is part of the health care sector. Shares are down 0.8% year-to-date as of the close of trading on Monday. Currently there are 7 analysts who rate Amgen a buy, no analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates Amgen as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, revenue growth, reasonable valuation levels and expanding profit margins. We feel its strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Amgen Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading, Biogen ( BIIB) is up $4.26 (1.1%) to $400.47 on light volume. Thus far, 548,351 shares of Biogen exchanged hands as compared to its average daily volume of 1.6 million shares. The stock has ranged in price between $396.66-$404.24 after having opened the day at $403.55 as compared to the previous trading day's close of $396.21.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Biogen Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurological, autoimmune, and hematologic disorders in the United States and internationally. Biogen has a market cap of $96.1 billion and is part of the health care sector. Shares are up 20.4% year-to-date as of the close of trading on Monday. Currently there are 11 analysts who rate Biogen a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Biogen as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, robust revenue growth and largely solid financial position with reasonable debt levels by most measures. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Biogen Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading, Gilead ( GILD) is up $1.66 (1.4%) to $117.12 on average volume. Thus far, 5.0 million shares of Gilead exchanged hands as compared to its average daily volume of 11.0 million shares. The stock has ranged in price between $116.78-$118.30 after having opened the day at $117.29 as compared to the previous trading day's close of $115.46.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical need in North America, South America, Europe, and the Asia-Pacific. Gilead has a market cap of $175.6 billion and is part of the health care sector. Shares are up 22.5% year-to-date as of the close of trading on Monday. Currently there are 14 analysts who rate Gilead a buy, 1 analyst rates it a sell, and 1 rates it a hold.

TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and notable return on equity. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Gilead Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

More from Markets

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists